Laurus Labs receives EIR from USFDA for manufacturing plant at Vishakhapatnam

16 Sep 2017 Evaluate

Laurus Labs has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its Finished Dosage Formulations (FDF) & Active Pharmaceutical Ingredients (API) manufacturing plant, Unit 2, located at Atchutapuram, Vishakhapatnam, for the inspection completed in May 2017.

Besides, Unit 2 (FDF) has also completed the BGV Hamburg (German Regulatory Authority) inspection and Units 1 & 3 located at Parawada, Visakhapatnam have completed WHO (Geneva) inspection successfully during this month with no critical or major observations.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.


Laurus Labs Share Price

491.90 6.75 (1.39%)
31-Oct-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.05
Dr. Reddys Lab 1274.25
Cipla 1553.20
Lupin 2184.00
Zydus Lifesciences 1001.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.